Published in Vaccine Weekly, November 7th, 2001
Under the terms of the five-year agreement, Merck will provide proprietary technology and experience in HIV biology and CAT will provide its proprietary human phage antibody libraries. Merck receives exclusive rights to prophylactic and therapeutic products developed in collaboration with CAT against the specified viral target. CAT will receive an upfront technology access fee from Merck, clinical development milestones, and royalties on the sale of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly